Cryo-Cell Faces License Termination by Duke University

Cryo-Cell International ( (CCEL) ) has issued an update.

Cryo-Cell International, Inc. has received a notice of termination from Duke University regarding their Patent and Technology License Agreement, effective May 17, 2025. The termination is based on Duke’s claim that Cryo-Cell breached the agreement, following Cryo-Cell’s arbitration demand alleging fraudulent inducement and multiple breaches by Duke.

The most recent analyst rating on (CCEL) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.

Spark’s Take on CCEL Stock

According to Spark, TipRanks’ AI Analyst, CCEL is a Neutral.

Cryo-Cell International’s overall stock score is impacted by moderate financial performance, highlighted by strong cash flow but significant balance sheet issues, including negative equity. The technical analysis indicates a bearish trend, which, combined with overvaluation concerns, further pressures the stock. The recent decision to reduce the dividend signals cautious financial management, contributing to a lower score.

To see Spark’s full report on CCEL stock, click here.

More about Cryo-Cell International

Cryo-Cell International, Inc. operates in the biotechnology industry, focusing on the collection and storage of umbilical cord blood and tissue for potential future medical use.

Average Trading Volume: 13,206

Technical Sentiment Signal: Sell

Current Market Cap: $42.35M

For a thorough assessment of CCEL stock, go to TipRanks’ Stock Analysis page.